CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-198232 | Pharmaceuticals
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET
7.1 GLOBAL CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA CHEMOTHERAPHY INDUCED NAUSEA AND VOMITTING (CINV) DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 GlaxoSmithKline
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Helsinn
16.3 Heron Therapeutics
16.4 Merck & Co
16.5 Tesaro
16.6 Acacia Pharma
16.7 Aphios
16.8 Barr Laboratories
16.9 Baxter Healthcare
16.10 Eisai
16.11 Especificos Stendhal
16.12 FHoffmann La Roche
16.13 Mundipharma
16.14 Mylan Pharmaceuticals
16.15 OPKO Health
16.16 Orchid Healthcare
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
Market by Type :Aloxi (palonosetron)
Kytril Generic (granisetron)
Emend (aprepitant)
Akynzeo (netupitant-palonosetron)
Market by Application :
Blood Cancer
Breast Cancer
Gastrointestinal Tract Cancer
Others
Companies
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck & Co
Tesaro
Acacia Pharma
Aphios
Barr Laboratories
Baxter Healthcare
Eisai
Especificos Stendhal
FHoffmann La Roche
Mundipharma
Mylan Pharmaceuticals
OPKO Health
Orchid Healthcare
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.